AU2011344865B2 - Entrapment of radionuclides in nanoparticle compositions - Google Patents

Entrapment of radionuclides in nanoparticle compositions Download PDF

Info

Publication number
AU2011344865B2
AU2011344865B2 AU2011344865A AU2011344865A AU2011344865B2 AU 2011344865 B2 AU2011344865 B2 AU 2011344865B2 AU 2011344865 A AU2011344865 A AU 2011344865A AU 2011344865 A AU2011344865 A AU 2011344865A AU 2011344865 B2 AU2011344865 B2 AU 2011344865B2
Authority
AU
Australia
Prior art keywords
lll
loading
nanoparticles
nanoparticle composition
leakage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011344865A
Other languages
English (en)
Other versions
AU2011344865A1 (en
Inventor
Thomas Lars Andresen
Jonas Rosager Henriksen
Andreas Kjaer
Anncatrine Luisa Petersen
Palle Hedengran Rasmussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigshospitalet
Danmarks Tekniske Universitet
Original Assignee
Rigshospitalet
Danmarks Tekniske Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet, Danmarks Tekniske Universitet filed Critical Rigshospitalet
Publication of AU2011344865A1 publication Critical patent/AU2011344865A1/en
Application granted granted Critical
Publication of AU2011344865B2 publication Critical patent/AU2011344865B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A61K51/1237—Polymersomes, i.e. liposomes with polymerisable or polymerized bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0408—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2011344865A 2010-12-14 2011-12-14 Entrapment of radionuclides in nanoparticle compositions Ceased AU2011344865B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA201070542 2010-12-14
DKPA201070542 2010-12-14
US201161434070P 2011-01-19 2011-01-19
EP11151372 2011-01-19
US61/434,070 2011-01-19
EP11151372.7 2011-01-19
PCT/DK2011/050479 WO2012079582A1 (en) 2010-12-14 2011-12-14 Entrapment of radionuclides in nanoparticle compositions

Publications (2)

Publication Number Publication Date
AU2011344865A1 AU2011344865A1 (en) 2013-07-11
AU2011344865B2 true AU2011344865B2 (en) 2017-03-09

Family

ID=45445682

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011344865A Ceased AU2011344865B2 (en) 2010-12-14 2011-12-14 Entrapment of radionuclides in nanoparticle compositions

Country Status (10)

Country Link
US (2) US9226984B2 (https=)
EP (1) EP2651447B1 (https=)
JP (1) JP5947807B2 (https=)
KR (1) KR20140092226A (https=)
AU (1) AU2011344865B2 (https=)
BR (1) BR112013014735A2 (https=)
CA (1) CA2821024A1 (https=)
DK (1) DK2651447T3 (https=)
RU (1) RU2013132610A (https=)
WO (1) WO2012079582A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013249307B2 (en) 2012-04-17 2017-11-09 Merrimack Pharmaceuticals, Inc. Compositions and methods for non-invasive imaging
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
WO2015061592A1 (en) * 2013-10-23 2015-04-30 Merrimack Pharmaceuticals, Inc. Liposomes for non-invasive imaging and drug delivery
TW201615229A (zh) * 2014-10-23 2016-05-01 行政院原子能委員會核能研究所 製備放射標靶藥物的套件及放射標靶藥物之製造方法
AU2016256979B2 (en) 2015-05-04 2021-01-28 Genfit Method for preparing transmembrane pH-gradient vesicles
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
EP3337467B1 (en) 2015-08-20 2020-12-09 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
MX385425B (es) 2015-08-21 2025-03-18 Ipsen Biopharm Ltd Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico.
RU2599462C1 (ru) * 2015-09-22 2016-10-10 Общество с ограниченной ответственностью "БИОТЕХНОЛОГИЯ" (ООО "БИОТЕХНОЛОГИЯ") Способ полисигнальной активации апоптоза клеток злокачественных солидных опухолей
MX382522B (es) 2015-10-16 2025-03-13 Ipsen Biopharm Ltd Composiciones farmaceuticas estabilizantes de camptotecina.
EP3354270A4 (en) * 2016-10-21 2019-04-24 Obshestvo S Ogranichennoi Otvetstvennost'yu "Biotehnologiya" METHOD FOR ACTIVATION OF APOPTOSIS OF CELLS WITH MULTIPLE SIGNALING OF SOLID MALIGNANT TUMORS
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
EP3773996A4 (en) 2018-03-26 2022-03-30 Triumf Systems, apparatus and methods for separating actinium, radium, and thorium
CN109063231B (zh) * 2018-06-15 2023-06-27 中国核电工程有限公司 基于GUM导则的核素不确定度对临界系统keff影响的评定方法
EP3917499A4 (en) * 2019-01-29 2022-10-19 The Johns Hopkins University Adhesive/adsorption switch on nanoparticles to increase tumor uptake and delay tumor clearance
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
WO2023183559A1 (en) * 2022-03-24 2023-09-28 The Brigham And Women's Hospital, Inc. Engineered ionophores for transport of metal ions
WO2024258223A1 (ko) * 2023-06-14 2024-12-19 주식회사 지티아이바이오사이언스 방사성 동위원소를 포함하는 나노입자 조성물을 제조하는 장치 및 이의 제조 방법
FR3156311A1 (fr) * 2023-12-08 2025-06-13 Aken Medical Nanoparticules radioactives de type cœur/enveloppe utiles en radiothérapie ciblée
FR3156312A1 (fr) * 2023-12-08 2025-06-13 Aken Medical Nanoparticules radioactives de type cœur/enveloppes utiles en radiothérapie ciblée

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003041682A2 (en) * 2001-11-13 2003-05-22 Celator Technologies, Inc. Lipid carrier compositions and methods for improved drug retention

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310506A (en) 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
US5622713A (en) 1985-09-17 1997-04-22 The Regents Of The University Of California Method of detoxifying animal suffering from overdose
ATE88642T1 (de) 1987-11-04 1993-05-15 Vestar Inc Zusammensetzung und verfahren zur anwendung von in liposomen eingeschlossenen verbindungen in der neutroneneinfangtherapie von tumoren.
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5525232A (en) 1990-03-02 1996-06-11 The Liposome Company, Inc. Method for entrapment of cationic species in lemellar vesicles
JPH075561B2 (ja) 1991-12-17 1995-01-25 工業技術院長 α−アミノ酸のジアミド誘導体
CA2093381A1 (en) * 1992-04-07 1993-10-08 Hideyuki Sawahara Liposome formulation and process for production thereof
US5837282A (en) * 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6106858A (en) * 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
US5945502A (en) 1997-11-13 1999-08-31 Xerox Corporation Electroluminescent polymer compositions and processes thereof
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
WO2003011345A1 (en) * 2001-07-27 2003-02-13 Targesome, Inc. Lipid constructs as therapeutic and imaging agents
KR20040091076A (ko) * 2002-02-26 2004-10-27 아마토 세이야쿠 가부시키가이샤 리포솜에의 금속착체의 봉입방법
EP1603535A4 (en) 2003-03-18 2008-10-15 Ethicon Inc AROMATASE HEMMER DIAGNOSIS AND THERAPY
EP1616182A4 (en) 2003-03-18 2008-04-16 Ethicon Inc ENZYMERSATZ THERAPY WITH 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2
JP2006045132A (ja) * 2004-08-05 2006-02-16 Konica Minolta Medical & Graphic Inc リポソーム含有磁気共鳴造影剤
US20060040980A1 (en) 2004-08-20 2006-02-23 Lind Stuart E Ionophores as cancer chemotherapeutic agents
GB0423565D0 (en) 2004-10-22 2004-11-24 Algeta As Formulation
ITMI20050328A1 (it) 2005-03-03 2006-09-04 Univ Degli Studi Milano Composti peptidomimetrici e preparazione di derivati biologicamente attivi
TW200922630A (en) 2007-09-26 2009-06-01 Nat Health Research Institutes Liposome compositions useful for tumor imaging and treatment
WO2009140215A2 (en) 2008-05-11 2009-11-19 Geraghty, Erin Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
JP5429710B2 (ja) * 2009-03-30 2014-02-26 独立行政法人放射線医学総合研究所 治療薬剤の標的部位への集積及び放出を追跡可能な治療薬剤含有リポソームおよびその製造方法
CA2768444A1 (en) 2009-07-17 2011-01-20 Rigshospitalet Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003041682A2 (en) * 2001-11-13 2003-05-22 Celator Technologies, Inc. Lipid carrier compositions and methods for improved drug retention

Also Published As

Publication number Publication date
JP2014506240A (ja) 2014-03-13
DK2651447T3 (en) 2018-12-17
EP2651447B1 (en) 2018-08-29
US9226984B2 (en) 2016-01-05
EP2651447A1 (en) 2013-10-23
BR112013014735A2 (pt) 2016-10-04
RU2013132610A (ru) 2015-01-20
JP5947807B2 (ja) 2016-07-06
CA2821024A1 (en) 2012-06-21
KR20140092226A (ko) 2014-07-23
US20160158392A1 (en) 2016-06-09
WO2012079582A1 (en) 2012-06-21
AU2011344865A1 (en) 2013-07-11
US20130251630A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
AU2011344865B2 (en) Entrapment of radionuclides in nanoparticle compositions
US8920775B2 (en) Loading technique for preparing radionuclide containing nanoparticles
Soundararajan et al. [186Re] Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model
EP3193914B1 (en) Organ protection in psma-targeted radionuclide therapy of prostate cancer
AU2001237827B2 (en) Radioactive therapeutic liposomes
Jensen et al. Remote-loading of liposomes with manganese-52 and in vivo evaluation of the stabilities of 52Mn-DOTA and 64Cu-DOTA using radiolabelled liposomes and PET imaging
MX2013000501A (es) Radioterapia guiada por nanoparticulas.
Kaul et al. Targeted theranostic liposomes: rifampicin and ofloxacin loaded pegylated liposomes for theranostic application in mycobacterial infections
US20090081121A1 (en) Liposome compositions useful for tumor imaging and treatment
WO2023014975A1 (en) Methods for biological material labeling and medical imaging
WO2012054717A2 (en) Detecting and treating solid tumors through selective disruption of tumor vasculature
CN116143826A (zh) 一种有助于诊疗的新型硼脂质体
Ahmad The Use of Bioorthogonal Chemistry to Create 99mTc and Micelle-based Diagnostic Agents
Laverman et al. Radiolabeling of liposomes for scintigraphic imaging
Prasad ALPHA-PARTICLE NANOTHERAPEUTICS AGAINST METASTATIC AND/OR CHEMORESISTANT TRIPLE NEGATIVE BREAST CANCER
Amanlou et al. Magnetic resonance contrast media sensing in vivo molecular imaging agents: an overview
Gregory Radiolabeling of Liposomes for Scintigraphic Imaging
Hsu et al. Liposomes labeled with Indium-111 by a novel surface labeling method exhibits good biodistribution in vivo

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired